CD274 and metastatic neoplasm: While immunotherapy with the PD-L1-inhibitor atezolizumab prolongs progression-free survival in patients with PD-L1-positive TNBC when added to nab-paclitaxel, chemotherapy remains the standard treatment for metastatic disease and results in a median survival of 12–18 months [1].